MX2016014756A - Nuevo tratamiento. - Google Patents
Nuevo tratamiento.Info
- Publication number
- MX2016014756A MX2016014756A MX2016014756A MX2016014756A MX2016014756A MX 2016014756 A MX2016014756 A MX 2016014756A MX 2016014756 A MX2016014756 A MX 2016014756A MX 2016014756 A MX2016014756 A MX 2016014756A MX 2016014756 A MX2016014756 A MX 2016014756A
- Authority
- MX
- Mexico
- Prior art keywords
- cftr
- trimethylphenylimino
- pyrimido
- isoquinolin
- carbamoyl
- Prior art date
Links
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 4
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- CSOBIBXVIYAXFM-UHFFFAOYSA-N rpl-554 Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2CCNC(N)=O)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C CSOBIBXVIYAXFM-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000009890 sinusitis Diseases 0.000 abstract 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000024632 Idiopathic bronchiectasis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000007466 Male Infertility Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010033649 Pancreatitis chronic Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 210000001177 vas deferen Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona un compuesto para uso en el tratamiento o prevención de una enfermedad o afección seleccionada de fibrosis quística, enfermedad pulmonar obstructiva crónica (COPD), asma, enfermedad pulmonar leve, bronquitis, bronquiectasia, bronquiectasia idiopática, aspergilosis broncopulmonar alérgica, sinusitis, rinosinusitis, síndrome metabólico relacionado con CFTR (CRMS), pancreatitis, pancreatitis crónica idiopática y síndrome de Sjörgren, o para su uso en la prevención de la infertilidad masculina causada por la ausencia congénita de los conductos deferentes, en un paciente mediante la modulación de la actividad de CFTR, cuyo compuesto es 9,10-dimetoxi-2-(2,4,6-trimetilfenilimino)-3-(N-carbamoil-2-amino etil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]isoquinolin-4-ona o una sal de adición de ácido farmacéuticamente aceptable del mismo. La invención también proporciona una composición que comprende (i) 9,10-dimetoxi-2-(2,4,6-trimetilfenilimino)-3-(N-carb amoil-2-aminoetil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]isoquinol in-4-ona o una sal de adición de ácido farmacéuticamente aceptable del mismo y (ii) un antagonista del receptor de leucotrieno. La invención también proporciona una composición que comprende (i) 9,10-dimetoxi-2-(2,4,6-trimetilfenilimino)-3-(N-carb amoil-2-aminoetil)-3,4,6,7-tetrahidro-2H-pirimido[6,1-a]isoquinol in-4-ona o una sal de adición de ácido farmacéuticamente aceptable del mismo y (ii) un potenciador de CFTR o un corrector de CFTR.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1408384.4A GB201408384D0 (en) | 2014-05-12 | 2014-05-12 | New treatment |
| GBGB1417719.0A GB201417719D0 (en) | 2014-10-07 | 2014-10-07 | New treatment |
| PCT/GB2015/051377 WO2015173551A1 (en) | 2014-05-12 | 2015-05-11 | New treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016014756A true MX2016014756A (es) | 2017-03-23 |
Family
ID=53264683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014756A MX2016014756A (es) | 2014-05-12 | 2015-05-11 | Nuevo tratamiento. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10864213B2 (es) |
| EP (2) | EP3231444B1 (es) |
| AU (1) | AU2015261239B2 (es) |
| CA (1) | CA2948620C (es) |
| CY (2) | CY1120550T1 (es) |
| DK (2) | DK3231444T3 (es) |
| ES (2) | ES2682105T3 (es) |
| HU (1) | HUE048020T2 (es) |
| IL (1) | IL248856B (es) |
| MX (1) | MX2016014756A (es) |
| PL (2) | PL3231444T3 (es) |
| PT (2) | PT3142701T (es) |
| RU (1) | RU2688191C2 (es) |
| SI (2) | SI3142701T1 (es) |
| WO (1) | WO2015173551A1 (es) |
| ZA (1) | ZA201607705B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2790700T3 (es) | 2005-12-28 | 2020-10-28 | Vertex Pharma | Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CA3108488A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
| IL303422A (en) | 2014-04-15 | 2023-08-01 | Vertex Pharma | Pharmaceutical preparations for the treatment of diseases related to cystic fibrosis transmembrane conductance regulator modulators |
| HUE048020T2 (hu) | 2014-05-12 | 2020-05-28 | Verona Pharma Plc | Új kezelés |
| ES2875584T3 (es) | 2014-09-15 | 2021-11-10 | Verona Pharma Plc | Formulación para inhalación líquida que comprende RPL554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB201911517D0 (en) * | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| CA3160752A1 (en) * | 2019-12-26 | 2021-07-01 | Preston E. BRATCHER | Methods of treating cystic fibrosis transmembrane conductance regulator (cftr) dysfunction |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE455946B (sv) | 1986-10-20 | 1988-08-22 | Trion Forskning & Utveckling | Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| AU2178392A (en) | 1991-06-12 | 1993-01-12 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| ES2159678T3 (es) | 1991-12-18 | 2001-10-16 | Minnesota Mining & Mfg | Formulaciones de aerosol en suspension. |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| JP2002512183A (ja) | 1998-04-18 | 2002-04-23 | グラクソ グループ リミテッド | 医薬用エアゾール製剤 |
| GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| CA2368413C (en) * | 1999-03-31 | 2008-07-29 | Vernalis Limited | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| ATE233084T1 (de) | 1999-04-14 | 2003-03-15 | Glaxo Group Ltd | Pharmazeutische aerosolformulierung |
| EP2489659B1 (en) | 2004-06-24 | 2017-12-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| KR101587389B1 (ko) | 2008-11-06 | 2016-01-28 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ-결합 카세트 수송자의 조절자 |
| CN102482318B (zh) | 2009-09-11 | 2015-11-25 | 奇斯药制品公司 | 异噁唑烷衍生物 |
| MX345802B (es) | 2010-08-09 | 2017-02-16 | Verona Pharma Plc * | Forma cristalina de compuesto pirimido [6, 1-a] isoquinolin-4-ona. |
| CA2820600A1 (en) | 2010-11-26 | 2012-05-31 | Chiesi Farmaceutici S.P.A. | Glycine derivatives and their use as muscarinic receptor antagonists |
| WO2012107364A1 (en) | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
| CA2845039A1 (en) * | 2011-08-18 | 2013-02-21 | Shire Ag | Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy |
| EP2819670A1 (en) * | 2012-02-27 | 2015-01-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| DE212014000071U1 (de) | 2013-03-14 | 2015-11-04 | Lincoln Global, Inc. | Systeme zum Exportieren oder Verwenden von Schweisssequenzerdaten für externe Systeme |
| PT2968313T (pt) | 2013-03-15 | 2018-02-21 | Verona Pharma Plc | Combinação de fármacos |
| HUE048020T2 (hu) | 2014-05-12 | 2020-05-28 | Verona Pharma Plc | Új kezelés |
| ES2875584T3 (es) | 2014-09-15 | 2021-11-10 | Verona Pharma Plc | Formulación para inhalación líquida que comprende RPL554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB202002786D0 (en) | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
-
2015
- 2015-05-11 HU HUE17174446A patent/HUE048020T2/hu unknown
- 2015-05-11 SI SI201530328T patent/SI3142701T1/en unknown
- 2015-05-11 PL PL17174446T patent/PL3231444T3/pl unknown
- 2015-05-11 EP EP17174446.9A patent/EP3231444B1/en active Active
- 2015-05-11 AU AU2015261239A patent/AU2015261239B2/en active Active
- 2015-05-11 MX MX2016014756A patent/MX2016014756A/es active IP Right Grant
- 2015-05-11 RU RU2016148447A patent/RU2688191C2/ru active
- 2015-05-11 PL PL15724354T patent/PL3142701T3/pl unknown
- 2015-05-11 ES ES15724354.4T patent/ES2682105T3/es active Active
- 2015-05-11 DK DK17174446.9T patent/DK3231444T3/da active
- 2015-05-11 WO PCT/GB2015/051377 patent/WO2015173551A1/en active Application Filing
- 2015-05-11 PT PT15724354T patent/PT3142701T/pt unknown
- 2015-05-11 SI SI201531105T patent/SI3231444T1/sl unknown
- 2015-05-11 CA CA2948620A patent/CA2948620C/en active Active
- 2015-05-11 DK DK15724354.4T patent/DK3142701T3/en active
- 2015-05-11 US US15/310,693 patent/US10864213B2/en active Active
- 2015-05-11 PT PT171744469T patent/PT3231444T/pt unknown
- 2015-05-11 EP EP15724354.4A patent/EP3142701B1/en active Active
- 2015-05-11 ES ES17174446T patent/ES2773142T3/es active Active
-
2016
- 2016-11-08 ZA ZA2016/07705A patent/ZA201607705B/en unknown
- 2016-11-09 IL IL248856A patent/IL248856B/en active IP Right Grant
-
2018
- 2018-08-09 CY CY20181100831T patent/CY1120550T1/el unknown
-
2020
- 2020-02-19 CY CY20201100153T patent/CY1122748T1/el unknown
- 2020-11-16 US US17/099,598 patent/US11759467B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI3231444T1 (sl) | 2020-04-30 |
| HUE048020T2 (hu) | 2020-05-28 |
| SI3142701T1 (en) | 2018-08-31 |
| US20210106585A1 (en) | 2021-04-15 |
| EP3231444A1 (en) | 2017-10-18 |
| AU2015261239A1 (en) | 2016-12-01 |
| US11759467B2 (en) | 2023-09-19 |
| AU2015261239B2 (en) | 2020-02-27 |
| RU2016148447A3 (es) | 2018-12-27 |
| DK3142701T3 (en) | 2018-08-13 |
| CA2948620C (en) | 2023-01-24 |
| EP3142701B1 (en) | 2018-06-27 |
| PT3231444T (pt) | 2020-03-05 |
| US10864213B2 (en) | 2020-12-15 |
| PT3142701T (pt) | 2018-10-18 |
| ZA201607705B (en) | 2020-05-27 |
| CA2948620A1 (en) | 2015-11-19 |
| ES2773142T3 (es) | 2020-07-09 |
| IL248856B (en) | 2020-07-30 |
| PL3142701T3 (pl) | 2018-11-30 |
| RU2688191C2 (ru) | 2019-05-21 |
| IL248856A0 (en) | 2017-01-31 |
| ES2682105T3 (es) | 2018-09-18 |
| CY1120550T1 (el) | 2019-07-10 |
| PL3231444T3 (pl) | 2020-05-18 |
| EP3231444B1 (en) | 2019-12-18 |
| EP3142701A1 (en) | 2017-03-22 |
| RU2016148447A (ru) | 2018-06-19 |
| CY1122748T1 (el) | 2021-03-12 |
| US20170112839A1 (en) | 2017-04-27 |
| DK3231444T3 (da) | 2020-03-16 |
| WO2015173551A1 (en) | 2015-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016014756A (es) | Nuevo tratamiento. | |
| MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
| SA519402319B1 (ar) | Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز | |
| WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
| JP2015199769A5 (es) | ||
| PH12015500460B1 (en) | Coated pharmaceutical composition containing regorafenib | |
| MX2021005207A (es) | Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida. | |
| PH12018501236A1 (en) | Pharmaceutical composition comprising a potent inhibitor urat1 | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| MX2024009886A (es) | Derivados de quinolina como inhibidores de integrina alfa4beta7. | |
| TN2016000556A1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| JP2017537954A5 (es) | ||
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| MX371178B (es) | Orvepitant para el tratamiento de la tos crónica. | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| JO3610B1 (ar) | مشتقات كربوكساميد | |
| JOP20200127A1 (ar) | مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية | |
| MX2023001721A (es) | Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer. | |
| TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
| PH12020550932A1 (en) | Compositions and methods for treating or preventing vasomotor symptoms | |
| TR201720845A1 (tr) | Oral farmasöti̇k terki̇pler | |
| PH12016502247A1 (en) | Carboxamide derivatives | |
| NZ747821A (en) | Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |